Boston Scientific Gains Neuro, Cardiovascular Access Devices Via Acquisition
This article was originally published in The Gray Sheet
Executive SummaryMicrofabricated guidewires to facilitate interventional cardiology procedures will be developed by Boston Scientific, following the purchase of Precision Vascular Systems, Inc
You may also be interested in...
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.